Savita Rangarajan

Publications

86 publications

Page 5 of 9

The incidence of factor VIII inhibitors in severe haemophilia A following a major switch from full‐length to B‐domain‐deleted factor VIII: a prospective cohort comparison

C. R. M. Hay, B. P. Palmer, E. A. Chalmers, D. P. Hart, R. Liesner, S. Rangarajan, K. Talks, M. Williams & P. W. Collins, 2015, Haemophilia, 21(2), 219-226

DOI: 10.1111/hae.12563

Type: article

[Poster Presentation] Nonacog Beta Pegol (N9-GP) In Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Paediatric Haemophilia B Patients

M. Carcao, M. Zak, F.A. Karim, H. Hanabusa, S. Kearney, Y.M. Lu, P. Persson, S. Rangarajan & E. Santagostino, 2015, Haemophilia, 21 S2

Type: conference

[Poster Presentations] Long-Term Safety and Efficacy of Recombinant Factor VIII FC (RFVIIIFC) in Adults and Adolescents With Severe Haemophilia A: An Interim Analysis of The ASPIRE Study

J. Pasi, D. Perry, J. Mahlangu, B. Konkle, S. Rangarajan, S.A. Brown, H. Hanabusa, S. Jackson, I. Pabinger, L. M. Cristiano, X. Li, G.F. Pierce & G. Allen, 2015, Haemophilia, 21(S2), 52-53

Type: conference

A national survey of immunosuppression strategies for acquired haemophilia A

P. Batty, B. Palmer, E. Chalmers, C. R. M. Hay, R. Liesner, S. Rangarajan, K. Talks, M. Williams, P. Collins & D. P. Hart, 2015, Haemophilia, 21(1), e73-e76

DOI: 10.1111/hae.12547

Type: article

Pharmacokinetic and pharmacodynamic properties of plasma-derived vs. recombinant factor IX in patients with hemophilia B: a prospective crossover study

J. Alamelu, D. Bevan, B. Sorensen & S. Rangarajan, 2014, Journal of Thrombosis and Haemostasis, 12(12), 2044-2048

DOI: 10.1111/jth.12756

Type: article

Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011

Peter W Collins, Benedict P Palmer, Elizabeth A Chalmers, Daniel P Hart, Ri Liesner, Savita Rangarajan, Katherine Talks, Michael Williams & Charles R M Hay, 2014, Blood, 124(23), 3389-3397

DOI: 10.1182/blood-2014-07-580498

Type: article

Long-term safety and efficacy of factor IX gene therapy in hemophilia B

Amit C. Nathwani, Ulreke M. Reiss, Edward G.d. Tuddenham, Cecilia Rosales, Pratima Chowdary, Jenny Mcintosh, Marco Della Peruta, Elsa Lheriteau, Nishal Patel, Deepak Raj, Anne Riddell, Jun Pie, Savita Rangarajan, David Bevan, Michael Recht, Yu-min Shen, Kathleen G. Halka, Etiena Basner-tschakarjan, Federico Mingozzi, Katherine A. High, James Allay, Mark A. Kay, Catherine Y.c. Ng, Junfang Zhou, Maria Cancio, Christopher L. Morton, John T. Gray, Deokumar Srivastava, Arthur W. Nienhuis & Andrew M. Davidoff, 2014, New England Journal of Medicine, 371(21), 1994-2004

DOI: 10.1056/NEJMoa1407309

Type: article

Adult haemophilia A patients with inhibitors

Savita Rangarajan, V. Jiménez-Yuste & E. Santagostino, 2014, Haemophilia, 20(6), e414-e417

DOI: 10.1111/hae.12521

Type: letterEditorial

[Poster Presentation] A UKHCDO National Survey of the management of acquired haemophilia A

P. Batty, P.W. Collins, E. Chalmers, C.R. Hay, R. Liesner, B. Palmer, S. Rangarajan, K. Talks, M. Williams & D.P. Hart, 2014, Haemophilia, 20(s2), 31

Type: conference

The clinical implications of ADAMTS13 function

Savita Rangarajan, Craig Kessler & Louis Aledort, 2013, Thrombosis Research, 132(4), 403-407

DOI: 10.1016/j.thromres.2013.07.027